No Data
Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
ProMIS Neurosciences Advances in Alzheimer's Treatment Trial
ProMIS Neurosciences Reports Top-Line Data From The First Four Cohorts Of Its First-In-Human Phase 1a Clinical Trial Of PMN310 In Healthy Volunteers For Alzheimer's Disease Patients; Topline Results Demonstrated A Favorable Safety Profile And...
Express News | ProMIS Neurosciences Inc: Results Will Inform Dosing of Phase 1B Clinical Trial in Alzheimer's Patients, Which Is on Track to Initiate in H2
Express News | ProMIS Neurosciences: Topline Results Showed Dose Dependent Levels of Pmn310 Antibody in Cerebrospinal Fluid
Express News | ProMIS Neurosciences: Results Demonstrated Favorable Safety Profile and Tolerability Across Four Ascending Dose Levels in Healthy Volunteers
No Data